Compass Therapeutics Inc. reports results for the quarter ended June 30 - Earnings Summary

Compass Therapeutics

10/08/2026 14:31

Compass Therapeutics Inc. CMPX.OQ reported a quarterly adjusted loss of 13 cents​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of -14 cents.  The mean expectation of fifteen analysts for the quarter was for a loss of 11 cents per share. Wall Street expected results to range from -15 cents to -9 cents per share.
Reported revenue was zero​; analysts expected zero. 
Compass Therapeutics Inc.'s reported EPS for the quarter was a loss of 13 cents​.
The company reported a quarterly loss of $25.15 million.
Compass Therapeutics Inc. shares had fallen by 1.8% this quarter and lost 60.0% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had fallen by about 1.9% in the last three months.​ 
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 14 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy" 
Wall Street's median 12-month price target for Compass Therapeutics Inc. is $7.00, about 69.3% above its last closing price of $2.15
This summary was machine generated from LSEG data August 10 at 01:31 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
-0.11
-0.13
Missed
Mar. 31 2026 
-0.10
-0.10
Met
Dec. 31 2025 
-0.09
-0.09
Met
Sep. 30 2025 
-0.14
-0.08
Beat